Literature DB >> 21915770

Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed.

Pierre-Jean Guillausseau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21915770     DOI： 10.1007/s11892-011-0227-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  9 in total

Review 1.  Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

Authors:  Rury R Holman
Journal:  Metabolism       Date:  2006-05       Impact factor: 8.694

2.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

3.  UKPDS and the legacy effect.

Authors:  John Chalmers; Mark E Cooper
Journal:  N Engl J Med       Date:  2008-10-09       Impact factor: 91.245

4.  The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial.

Authors:  S Zoungas; J Chalmers; A P Kengne; A Pillai; L Billot; B de Galan; M Marre; B Neal; S Harrap; N Poulter; A Patel
Journal:  Diabetes Res Clin Pract       Date:  2010-06-11       Impact factor: 5.602

5.  Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Authors:  K Esposito; D Cozzolino; G Bellastella; M I Maiorino; P Chiodini; A Ceriello; D Giugliano
Journal:  Diabetes Obes Metab       Date:  2011-07       Impact factor: 6.577

6.  Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.

Authors:  Jo Satoh; Kazuma Takahashi; Yumiko Takizawa; Hisamitsu Ishihara; Masashi Hirai; Hideki Katagiri; Yoshinori Hinokio; Susumu Suzuki; Ichiro Tsuji; Yoshitomo Oka
Journal:  Diabetes Res Clin Pract       Date:  2005-06-08       Impact factor: 5.602

7.  Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?

Authors:  Bo Ahrén
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

8.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

9.  Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 17.152
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.